Clover Health stock drops on allegations it’s facing DOJ probe
‘Dr. Frankenstein’ of short selling says his firm will make a major shift
GameStop trading craze lifts shares of mining firm with same ticker
GameStop rally continues as officials raise possibility of foul play
The Securities and Exchange Commission is following up on a critical report about Clover Health by short-selling specialist Hindenburg Research and has told the insurance company to preserve any relevant documents.
Clover, backed by venture capitalist Chamath Palihapitiya, said Friday it would cooperate with the request from the SEC.
The company’s share price at noon Friday was down 2.1 percent, at $11.97.
Clover said the SEC had requested “document and data preservation for the period from January 1, 2020, to the present, relating to certain matters that are referenced in the (Hindenburg) article.”
The company also disclosed a separate earlier inquiry from the US Department of Justice, but added it had not received any civil investigative demands or subpoenas from the department.
Palihapitiya and the company were fully aware of the DOJ inquiry, which it did not consider as “material information” for its earlier disclosures, Clover said.
On Thursday, Hindenburg published a scathing report, the title of which called Clover a “broken business,” and accused the company of not disclosing a DOJ investigation into its business model and its software offering, Clover Assistant.
The insurance firm’s shares fell more than 12 percent, their biggest daily percentage drop in four months, following the report.
Clover said Friday some of the claims were “completely untrue” and executives Vivek Garipalli and Andrew Toy said in a separate blog post that the report was “rife with ad-hominem attacks, sweeping inaccuracies and gross mischaracterizations.”
Hindenburg was the first major short-selling research house to publish a new report since the eruption two weeks ago of the battle between short-sellers and investors over GameStop and a number of other stocks.
Clover, which sells Medicare-backed insurance plans, went public through a $3.7 billion deal with a special purpose acquisition company backed by Palihapitiya. Its other investors include Google parent Alphabet and Silicon Valley-based venture capital giant Sequoia Capital.
Share this article:
Source: Read Full Article